Forsta AP Fonden Has $15.60 Million Stake in HCA Healthcare, Inc. $HCA

Forsta AP Fonden reduced its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 42.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 33,420 shares of the company’s stock after selling 24,380 shares during the quarter. Forsta AP Fonden’s holdings in HCA Healthcare were worth $15,602,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Capital World Investors boosted its holdings in shares of HCA Healthcare by 3.8% during the 3rd quarter. Capital World Investors now owns 4,959,336 shares of the company’s stock valued at $2,113,662,000 after acquiring an additional 179,443 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of HCA Healthcare by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 3,663,705 shares of the company’s stock worth $1,702,738,000 after purchasing an additional 13,565 shares during the period. Norges Bank bought a new position in HCA Healthcare during the 4th quarter worth $1,262,513,000. Arrowstreet Capital Limited Partnership increased its stake in shares of HCA Healthcare by 1.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,065,225 shares of the company’s stock valued at $880,199,000 after buying an additional 36,414 shares during the period. Finally, Viking Global Investors LP lifted its stake in shares of HCA Healthcare by 58.5% in the second quarter. Viking Global Investors LP now owns 1,872,133 shares of the company’s stock worth $717,214,000 after acquiring an additional 690,773 shares during the period. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

HCA stock opened at $377.72 on Friday. The company has a market cap of $83.79 billion, a P/E ratio of 12.99, a price-to-earnings-growth ratio of 1.20 and a beta of 1.18. HCA Healthcare, Inc. has a fifty-two week low of $330.00 and a fifty-two week high of $556.52. The stock’s 50 day simple moving average is $451.94 and its 200 day simple moving average is $480.74.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Friday, April 24th. The company reported $7.15 earnings per share for the quarter, missing analysts’ consensus estimates of $7.19 by ($0.04). The firm had revenue of $19.11 billion for the quarter, compared to analyst estimates of $19.09 billion. HCA Healthcare had a negative return on equity of 295.93% and a net margin of 8.89%.HCA Healthcare’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the previous year, the company earned $6.45 earnings per share. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. Equities analysts predict that HCA Healthcare, Inc. will post 30.07 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 16th will be paid a $0.78 dividend. The ex-dividend date of this dividend is Tuesday, June 16th. This represents a $3.12 annualized dividend and a dividend yield of 0.8%. HCA Healthcare’s dividend payout ratio is 10.73%.

Analyst Ratings Changes

HCA has been the topic of a number of recent analyst reports. TD Cowen dropped their price target on shares of HCA Healthcare from $561.00 to $500.00 and set a “buy” rating on the stock in a research report on Monday, April 27th. Royal Bank Of Canada dropped their target price on shares of HCA Healthcare from $593.00 to $534.00 and set an “outperform” rating on the stock in a report on Monday, April 27th. Cantor Fitzgerald reissued an “overweight” rating on shares of HCA Healthcare in a research report on Wednesday, March 4th. Robert W. Baird lowered their target price on HCA Healthcare from $450.00 to $442.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Finally, Leerink Partners reduced their price objective on shares of HCA Healthcare from $573.00 to $500.00 and set an “outperform” rating for the company in a research report on Monday, April 27th. Sixteen equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $515.77.

About HCA Healthcare

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.